PAR2 promotes malignancy in lung adenocarcinoma.

导出 OA

翻译打印收藏纠错

第一作者： Bao,Wang

第一单位： Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University Tianjin 300070, China.;Jilin Cancer Hospital Changchun 130012, Jilin, China.

作者： Bao,Wang ^[1] ; Ming-Da,Wu ^[2] ; Yue-Jiao,Lan ^[2] ; Chun-Yi,Jia ^[3] ; Hui,Zhao ^[3] ; Kun-Peng,Yang ^[2] ; Hao-Nan,Liu ^[2] ; Shi-Zhuo,Sun ^[2] ; Ran-Cen,Tao ^[4] ; Xiao-Dan,Lu ^[2] ; Zhen-Fa,Zhang ^[4]

作者单位： Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University Tianjin 300070, China.;Jilin Cancer Hospital Changchun 130012, Jilin, China. ^[1] Precision Medicine Center, Jilin Province General Hospital Changchun 130021, Jilin, China. ^[2] Jilin Cancer Hospital Changchun 130012, Jilin, China. ^[3] Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University Tianjin 300070, China. ^[4]

关键词 Lung cancer PAR2 cisplatin lymphatic metastasis survival

DOI 10.62347/STSI5751

PMID 39822538

发布时间 2025-01-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交